Overview

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and toxicity levels of Dose Escalated Sorafenib in the treatment of patients with renal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute
The Methodist Hospital System
Collaborators:
Amgen
Bayer
Onyx Pharmaceuticals
Treatments:
Niacinamide
Sorafenib